TB-500 drug interactions: what the research actually shows

Last updated 2026-07-25

Does TB-500 interact with other drugs or medications?

Short answer: nobody actually knows, because nobody has run the study. Search PubMed for "TB-500 drug interaction" and you get zero controlled human trials. What exists is a small pile of analytical chemistry papers (how to detect the peptide in urine or plasma), a couple of in vitro wound-healing assays, and recent orthopaedic review articles that mention TB-500 in passing while discussing peptide therapy generally. A 2024 paper in the Journal of Chromatography B used UHPLC-Q-Exactive Orbitrap mass spec to track TB-500 and its metabolites in vitro and in rats, and separately screened wound-healing activity in vitro ^[1]. That's a metabolism and detection study, not a safety or interaction study. It tells you how the molecule breaks down and gets cleared, which matters for interaction reasoning, but it says nothing about what happens when you combine it with an NSAID, a blood thinner, or a corticosteroid. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics broadly, including the practical and regulatory challenges of using unapproved peptides in clinical practice ^[2]. A parallel 2026 piece in The American Journal of Sports Medicine frames itself as a primer for orthopaedic and sports medicine physicians on injectable peptide therapy ^[3]. Neither reports a controlled interaction trial for TB-500 specifically. They're best read as "here's the landscape doctors are dealing with," not as dosing or interaction guidance. The honest bottom line: any interaction claim you read online, including on TB-500 sourcing sites, is extrapolation from metabolism data and general knowledge of peptide biology. If someone tells you with confidence that TB-500 is safe or unsafe to combine with drug X, ask them for the citation. There usually isn't one.

Is TB-500 the same thing as thymosin beta-4?

No, and mixing these up is the single most common error in this space. Thymosin beta-4 is a naturally occurring 43-amino-acid protein in the body, involved in actin regulation and tissue repair signaling. TB-500 is a name used in the research-chemical market for a synthetic peptide built around an active fragment of that protein, not the full native molecule. The 2012 Drug Testing and Analysis paper on synthesis and characterization specifically describes the N-terminal acetylated 17-23 fragment of thymosin beta-4 identified in TB-500 products, flagging it as a substance of doping concern ^[4]. That's a fragment, roughly 7 amino acids out of the native protein's 43, chemically modified with acetylation. It is related to thymosin beta-4. It is not thymosin beta-4. Why does this matter for interactions? Because pharmacokinetics depend on molecular structure. A short acetylated fragment clears differently, binds differently, and metabolizes differently than the full-length native protein. Any interaction reasoning borrowed from "thymosin beta-4 studies" doesn't automatically transfer to TB-500 products, and vice versa. If you want the fuller breakdown of how these two get conflated, see TB4 peptide vs TB500.

What does the metabolism data suggest about interaction risk?

The 2024 UHPLC-Q-Exactive Orbitrap study is the closest thing to a mechanistic interaction clue we have, and it's an in vitro and rat study, not a human one ^[1]. It quantified TB-500 and its breakdown products, which at least tells researchers what the body does with the molecule once it's in circulation. General peptide pharmacology gives some reasoning, though it's inference, not proof. Peptides like TB-500 are broken down by proteolytic enzymes rather than liver cytochrome P450 pathways, which is the route that causes most classic small-molecule drug interactions (the ones you see with statins, blood thinners, or SSRIs). A 2016 Journal of Proteomics paper compared multiple in vitro model systems, proteolytic enzymes, human blood serum, liver and kidney microsomes, and liver S9 fraction, for metabolizing synthetic doping peptides generally ^[5]. That kind of modeling is what a pharmacologist would use to start reasoning about interaction potential, but it wasn't run specifically on TB-500 against named drugs, and it doesn't substitute for a real interaction trial. Practical takeaway: because TB-500 likely isn't processed through the CYP450 liver enzyme system the way most prescription drugs are, the textbook "interacts with warfarin because they compete for the same enzyme" type of interaction is less likely on paper. But less likely is not the same as ruled out, and injection-site and immune-response interactions (see below) are a separate category entirely that this reasoning doesn't cover.

Can I combine TB-500 with NSAIDs like ibuprofen or naproxen?

There's no published study answering this directly. What's worth knowing is the theoretical tension: NSAIDs work partly by blunting inflammation, and inflammation is the first phase of the tissue repair process that peptides like TB-500 are being researched for. Some orthopaedic sports medicine literature raises this exact concern for the broader injectable peptide category, not TB-500 specifically, noting that anti-inflammatory drugs could theoretically interfere with the biological cascade a regenerative therapy is trying to support ^[3]. That's a mechanistic concern, not a demonstrated interaction. Nobody has run a trial giving human subjects TB-500 plus ibuprofen and comparing outcomes to TB-500 alone. If you're already taking NSAIDs regularly for a chronic condition, that's a conversation for your prescribing physician, not something to sort out from a peptide forum.

Is it safe to combine TB-500 with BPC-157?

This is the most common real-world question, because TB-500 isn't sold as a standalone product in the first place. It's dispensed as a BPC-157/TB-500 blend through provider-reviewed channels, so the question of "can I combine these" is somewhat moot: if you're getting TB-500 at all, you're almost certainly getting it alongside BPC-157 already. The research base for the combination specifically is thin to nonexistent. Both peptides are studied mostly in isolation, in vitro or in animal models, for separate tissue-repair mechanisms (BPC-157's research centers on gut and tendon models, TB-500's on actin regulation and cell migration in wound healing) ^[1]. There is no published human trial testing the combined blend against either peptide alone, and no controlled data on whether combining them changes the interaction profile of either one with other medications. The recent 2026 Sports Medicine review on safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries covers this category of stacked, unapproved peptide use as a broader safety and evidence concern, not a green light ^[6]. If you want the deeper background on TB-500 as a research subject, TB-500 covers the evidence base in full.

Does TB-500 interact with blood thinners or anticoagulants?

No study has tested this combination. The theoretical concern people raise is injection-related, not a metabolic drug interaction. Any subcutaneous or intramuscular injection carries a bleeding and bruising risk that's higher if you're on warfarin, a DOAC like apixaban, or even regular aspirin. That's a mechanical risk from the injection itself, common to any injectable, not something specific to TB-500's pharmacology. Whether TB-500's own clearance or metabolism interacts with anticoagulant blood levels is unknown because it hasn't been studied. If you're on anticoagulant therapy, the injection-site bleeding risk alone is a reason to talk to the prescribing physician managing that medication before adding any injectable peptide, regardless of what's in the syringe.

Does TB-500 interact with steroids or hormone therapy?

Again, no direct study. The concern people raise online is usually about corticosteroids specifically, since steroids suppress inflammation and immune signaling, and TB-500's proposed mechanism in preclinical work involves cell migration and modulating inflammatory response during wound healing ^[1]. If a steroid is dampening the inflammatory signal a peptide might be working through, the two could theoretically blunt each other's effects. That's speculation extended from mechanism papers, not a result from a trial that tested both together. Anabolic-androgenic steroid users sometimes ask about TB-500 as an add-on for recovery. There's no data on that combination either. The gerontology-focused peptide review from 2026 discusses therapeutic peptides broadly in the context of healthy aging and tissue repair mechanisms, which touches on hormone-adjacent pathways in aging research generally, but it isn't a TB-500-plus-steroid interaction study ^[7].

Are there interactions between TB-500 and supplements or over-the-counter products?

Nothing published. Most of what circulates about TB-500 and supplement stacking (creatine, fish oil, vitamin D, collagen) is bodybuilding-forum reasoning, not data. None of the papers in the current research record, which is dominated by detection chemistry and animal metabolism work, address supplement co-administration ^{[8] [9] [10]}. If you're taking multiple supplements alongside any unapproved injectable peptide, the practical risk isn't a documented pharmacological interaction, it's that you won't be able to tell what's causing what if something goes wrong. That's a monitoring problem more than a chemistry problem.

Why is there so little interaction data on TB-500 specifically?

Because TB-500 has never gone through FDA drug approval, and most of the published research on it comes from two very different worlds that both stop short of clinical interaction testing. One world is doping control chemistry. A large share of the PubMed record on TB-500 exists because anti-doping labs needed methods to detect it. Papers cover doping control analysis in equine urine and plasma ^[9], adsorption effects during sample handling ^[10], synthesis and characterization for detection purposes ^[4], solid-phase extraction methods ^[11], and general reviews of detecting peptidic drugs in sports doping ^{[12] [13] [14] [5]}. This is real, careful analytical science. It answers "can we find this in a urine sample" and "how does it behave in a mass spectrometer," not "is it safe with drug X." The other world is basic tissue-repair and orthopaedic peptide research, which is preclinical (cell cultures, rodent models) and mostly mechanistic. The 2026 JAAOS Global Research & Reviews paper and the American Journal of Sports Medicine primer both discuss the regulatory and practical challenges facing orthopaedic physicians who encounter patients using peptides like this, which is a tell: the clinical community itself is flagging the evidence gap ^{[2] [3]}. Because TB-500 was never pushed through FDA phase I through III trials, it never generated the kind of formal drug-interaction studies that approved medications require. You can check any approved drug's interaction profile in Drugs@FDA's product labeling database ^[15]. TB-500 has no entry there, because it was never approved.

Is TB-500 legally regulated, and does that affect drug interaction testing?

TB-500 is not on the FDA's list of bulk drug substances that compounding pharmacies may legally use under Section 503A of the Federal Food, Drug, and Cosmetic Act ^[16], nor is it on the 503B outsourcing facility bulks list ^[17]. Those lists, found at 21 CFR 216.23 and 216.24 respectively ^{[18] [19]}, define what compounders can legally source and prepare. Compounding itself is governed by 21 U.S.C. 353a ^[20]. That regulatory status matters directly for interaction data: substances outside the approved drug pipeline don't go through FDA-mandated interaction studies, don't get formal labeling under 21 CFR 201.128's definition of intended use , and don't appear in Drugs@FDA ^[15]. Compare that to something like ibuprofen or metformin, where interaction data is extensive precisely because approval required it. For athletes specifically: TB-500 is prohibited under the World Anti-Doping Agency's list because it's a synthetic peptide related to thymosin beta-4, a substance class WADA and multiple anti-doping labs have built detection methods for, evidenced by the volume of doping-control chemistry papers cited above ^{[9] [10] [21] [4]}. If you compete under WADA or a WADA-affiliated body's testing program, TB-500 use carries real sanction risk independent of any drug-interaction question.

What should I actually do if I'm on other medications and considering TB-500?

Talk to the physician managing your existing medications before adding anything, full stop. That's not boilerplate, it's the only defensible move given how thin the interaction literature is. If you're already on anticoagulants, immunosuppressants, corticosteroids, or anything with a narrow therapeutic window, the absence of interaction data cuts against you, not for you. No study existing doesn't mean no risk exists, it means nobody has looked. Because there's no standalone TB-500 product, and it's dispensed as a BPC-157/TB-500 blend, you're also automatically dealing with two active substances at once, and the interaction question multiplies. TB-500 Co works with a provider-reviewed process and a fulfilling pharmacy partner precisely because a clinician reviewing your medication list before anything is dispensed is the only real mitigation available right now, given the state of the evidence. If you haven't looked at dosing basics yet, TB-500 cycle length and TB-500 how to inject are the logical next reads, along with TB-500 injection sites if injection-related bleeding risk from anticoagulants is your specific concern.

Frequently asked questions

Does TB-500 interact with prescription medications?

No published human study has tested TB-500 against any specific prescription drug. Interaction reasoning is currently based on general peptide metabolism data, not controlled trials, so anyone claiming a confirmed interaction (or confirmed safety) with a named drug is going beyond what the research supports.

Can you take TB-500 and BPC-157 together safely?

There's no controlled trial on the combination specifically. Practically, TB-500 is dispensed only as a BPC-157/TB-500 blend, not as a standalone product, so the question is largely built into how it's provided rather than an optional add-on decision.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is the native 43-amino-acid protein. TB-500 refers to a synthetic peptide built around an active fragment of it, described in the literature as an N-terminal acetylated 17-23 fragment, which behaves differently pharmacologically from the full native protein.

Does TB-500 show up on a drug test?

For general medical drug screens, no, it's not a standard panel item. For sports anti-doping testing, yes, it can be detected. Multiple published methods exist for finding TB-500 in urine and plasma using liquid chromatography-mass spectrometry, developed specifically for doping control labs.

Is TB-500 banned by WADA?

TB-500 is prohibited for athletes under anti-doping rules because it's synthesized from an active region of thymosin beta-4, a substance class anti-doping labs actively test for. The volume of published detection-method research in equine and human sample matrices reflects how seriously anti-doping bodies treat this substance.

Can TB-500 interact with NSAIDs like ibuprofen?

No direct study exists. The theoretical concern is that NSAIDs blunt inflammation, which is part of the tissue-repair cascade peptides like TB-500 are studied for, so combining them could in theory work against each other. This is mechanistic speculation, not a demonstrated clinical interaction.

Is TB-500 FDA approved?

No. TB-500 doesn't appear in the FDA's Drugs@FDA database of approved drug products, and it's not on the FDA's 503A or 503B bulk drug substance lists that govern what compounding pharmacies may legally use, meaning it was never approved through standard clinical trials.

Does TB-500 interact with blood thinners?

No study has tested this. The practical risk is mechanical, not chemical: any injection carries higher bruising and bleeding risk if you're on warfarin, a DOAC, or regular aspirin, regardless of what peptide is in the syringe.

Why isn't there more drug interaction research on TB-500?

Because it never went through FDA approval, which is what mandates formal interaction studies. Most published research on TB-500 instead comes from anti-doping detection chemistry or preclinical wound-healing and metabolism studies in cells and rodents, not human clinical trials.

Can I combine TB-500 with steroids or hormone therapy?

No published data addresses this combination. The theoretical concern is that corticosteroids suppress inflammatory signaling that TB-500's proposed mechanism may work through, potentially blunting effects, but this is inference from mechanism papers, not a tested result.

Is it safe to take TB-500 with supplements like creatine or fish oil?

No published study covers this. Nothing in the current TB-500 literature, which focuses on detection chemistry and animal metabolism, addresses supplement co-administration. The practical risk is that combining multiple substances makes it harder to identify a cause if a side effect occurs.

Can you buy TB-500 as a standalone product?

No. TB-500 is dispensed as part of a BPC-157/TB-500 blend, not sold on its own, through provider-reviewed sourcing channels. If a seller offers pure standalone TB-500 with no blend and no provider review, that's a red flag worth taking seriously.

Sources

1. Journal of Chromatography B (2024), PMID 38382158: UHPLC-Q-Exactive Orbitrap MS/MS study quantified TB-500 and its metabolites in vitro and in rats, and screened wound-healing activity in vitro
2. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews (2026), PMID 41490200: Review covers therapeutic peptides in orthopaedics, including applications, challenges, and future directions for clinical use
3. The American Journal of Sports Medicine (2026), PMID 41476424: Primer for orthopaedic and sports medicine physicians on injectable peptide therapy practice
4. Sports Medicine (Auckland, N.Z.) (2026), PMID 41966639: Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
5. Frontiers in Aging (2026), PMID 42021992: Review of therapeutic peptide mechanisms and applications for healthy aging
6. Journal of Pharmaceutical and Biomedical Analysis (2014), PMID 24906629: Analytical approaches developed for detecting emerging therapeutics and non-approved drugs in doping control
7. Journal of Chromatography A (2012), PMID 23084823: Doping control analysis method for TB-500 developed in equine urine and plasma using LC-MS
8. Analytical Biochemistry (2017), PMID 28887173: Study characterized adsorption effects of doping-relevant peptides including TB-500 during sample handling
9. Expert Review of Proteomics (2014), PMID 25382550: Review of current status and future directions for detecting peptidic drugs and analogs in sports doping
10. Drug Testing and Analysis (2012), PMID 22962027: Synthesis and characterization confirmed TB-500 contains the N-terminal acetylated 17-23 fragment of thymosin beta-4
11. Journal of Peptide Science (2015), PMID 25469748: In vitro models developed for metabolic studies of small peptide hormones in sport drug testing
12. Journal of Separation Science (2016), PMID 26578461: Method developed for screening peptides under 2 kDa via direct urine injection with LC and ion mobility mass spectrometry
13. Analytical and Bioanalytical Chemistry (2013), PMID 23318763: Doping control method developed for analyzing seven bioactive peptides in horse plasma by LC-MS
14. Journal of Proteomics (2016), PMID 27569051: Comparison of in vitro model systems (proteolytic enzymes, serum, liver/kidney microsomes, liver S9 fraction) for metabolizing synthetic doping peptides
15. Drug Testing and Analysis (2016), PMID 26472487: Solid-phase extraction method developed for small bioactive peptides from human urine using cartridges and microelution plates
16. FDA, Drugs@FDA database: TB-500 has no approved drug product listing, unlike FDA-approved drugs with formal interaction labeling
17. FDA, bulk drug substances used in compounding under Section 503A: FDA maintains the list of bulk substances legally usable in 503A compounding, which governs sourcing of substances like TB-500
18. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the 503B outsourcing facility bulk drug substances list
19. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the 503A bulk drug substances list governing compounding pharmacy sourcing
20. Cornell Law School LII, 21 U.S.C. 353a: Federal statute governing pharmacy compounding practices
21. eCFR, 21 CFR 201.128: Defines the meaning of intended uses for drug labeling purposes, relevant to why unapproved substances lack formal interaction labeling